Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2017 Financial Results on May 8, 2017

Tuesday, April 25, 2017 7:00 am EDT

Dateline:

WOODCLIFF LAKE, N.J.

Public Company Information:

NASDAQ:
EGRX

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. ("Eagle" or “the Company”) (Nasdaq:EGRX) announced today that the Company will release its 2017 first quarter financial results on Monday, May 8, 2017, before the market opens.

Scott Tarriff, Chief Executive Officer, and David E. Riggs, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date       Monday, May 8, 2017
Time 8:30 a.m. EDT
Toll free (U.S.) 888-632-3384
International 785-424-1675
Webcast (live and replay)

www.eagleus.com, under the “Investor Relations” section

 

A replay of the conference call will be available for one week after the call's completion by dialing 800-839-2475 (US) or 402-220-7220 (International) and entering conference call ID EGRXQ117. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.

Contact:

Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson, 212-452-2793
lwilson@insitecony.com